Lung, Phase III

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jennifer Pope

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Anne Chiang, MD, PhD
Associate Professor; Associate Cancer Center Director, Clinical Initiatives

Sub-Investigators

Last Updated
12/19/2024
Study HIC
#2000037528